Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Tharimmune, Inc. (NASDAQ:THAR), a volatile biotech stock that has surged nearly 200% over the past six months with a current market capitalization of $18.6 million, amended its Certificate of Incorporation on Friday to increase the number of authorized shares of its common stock from 250 million to 1 billion. The company filed the amendment with the Secretary of State of Delaware.
The change was disclosed in a press release statement and detailed in a filing with the Securities and Exchange Commission. Tharimmune’s common stock continues to trade on The Nasdaq Stock Market under the symbol THAR.
No other material changes to the company’s articles of incorporation or bylaws were reported in the filing.
In other recent news, Tharimmune, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after reporting stockholders’ equity of $6,876,335 as of August 31, 2025. This follows two recent registered direct offerings and a private placement that raised approximately $7.05 million in gross proceeds, ensuring the company meets the $2.5 million minimum equity requirement for continued listing on the Nasdaq Capital Market. Additionally, Tharimmune disclosed a $5.35 million direct offering of common stock, issuing 1,188,888 shares at $4.50 per share. The company also amended warrants to make 3.4 million shares immediately exercisable as of October 1, 2025. In another development, Tharimmune’s Compensation Committee approved a $100,000 increase in the base salaries of CEO Sireesh Appajosyula and Executive Chairman Vincent LoPriore, setting their new annual salaries at $385,000.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.